Author

N. Shah

h-index 5 View on Semantic Scholar

We have 3 of 51 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023)

Abstract Introduction Immune checkpoint inhibitors (ICI) have become standard of care for renal cell carcinoma (RCC) in the adjuvant, first-line and pre-treated settings. However, treatment patterns and outcomes of patients with RCC that progresses following ICI treatment are not well characterized. Methods A retrospec...

N. Shah, R. Ravilla, A. Osterland et al. · The Oncologist · 0 citations

Open access Sep 2026

24 A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-Pretreated Metastatic Clear Cell Renal Cell Carcinoma and Translocation-Associated Renal Cell Carcinoma (NCT06835972)

Abstract Background There is a need for novel systemic therapies in patients with metastatic renal cell carcinoma (RCC) who progress on standard agents. A hallmark of clear cell RCC (ccRCC) is von Hippel Lindau (VHL) inactivation which affects downstream targets including vascular endothelial growth factor (VEGF). It a...

Sahil D. Doshi, Y. Ged, Andrea Knezevic et al. · The Oncologist · 0 citations

Open access Aug 2026

Expanding the phenotype of hereditary renal cell carcinoma syndromes: Implications for surveillance and management.

Using large, unselected pan-cancer cohorts and integrated tumor and genomic analysis can help refine the phenotype of rare cancer predisposition syndromes and suggest novel cancer associations, including BAP1 PVs in hepatobiliary cancers and FLCN in colorectal cancer.

M. Carlo, Andrew Schroeder, Jie Liu et al. · Journal of the National Canc... · 0 citations